Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat

Medical Science Monitor

Volumn 9, Issue 5, 2003, Pages

  Wayman, Nicole S ^a   Ellis, Belinda L ^a   Thiemermann, Christoph ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Infarction; Myocardial ischemia; PPAR; Rat; Reperfusion injury; Simvastatin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITROBLUE TETRAZOLIUM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SIMVASTATIN; THIOPENTAL;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; THORACOTOMY; TISSUE NECROSIS;

ANIMALS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIMVASTATIN; TRANSCRIPTION FACTORS;

EID: 0038171189     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ohrvall M, Lithell H, Johansson J, Vessby B: A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. Metabolism, 1999; 44: 212-217
2. Bybee KA, Write RS, Kopecky SL: Effect of early statin therapy after acute coronary syndromes: A concise review of the recent data. Cardiol Rev, 2002; 12: 301-305
3. Leter AM, Campbell B, Shin YK et al: Simvastatin preserves the ischaemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation, 1999; 100: 178-184
4. Endres M, Laufs U. Huang Z et al: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci, 1998; 95: 8880-8885
5. Joyce M, Kelly C, Winter D, Chen G et al: Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. J Surg Res, 2001; 101: 79-84
6. Wagner AH, Schwabe O, Hecker M: Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br J Pharmacol, 2002; 136: 143-149
7. Node K, Kitakaze M, Kosaka H et al: Increased release of NO during ischaemia reduces myocardial contractility and improves metabolic dysfunctinn. Circulation, 1996; 93: 356-364
8. Balligand JL, Kelly RA, Marsden PA et al: Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acrid Sci USA, 1993; 90: 347-351
9. Hare JM, Loh E, Creager MA, Colucci WS: Nitric oxide inhibits the positive inotropic response to b-adrenergic stimulation in humans with left ventricular dysfunction. Circulation, 1995; 92: 2198-2203
10. Niwa S, Totsuka T, Hayashi S: Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol, 1996; 18: 669-675
11. Rosenson RS, Tangney CC, Casey LC: Inhibition of proinflammatory cytokine production by pravastatin. Lancet, 1999; 353: 983-984
12. Martin G, Duez H, Blanquart C et al: Statin-induced inhibition of the Rho-signaling pathway activites PPARalpha and induces HDL apoA-1. J Clin Invest, 2001; 107: 1423-1432
13. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S: Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res, 2002; 45: 147-154
14. Evans RM: The steroid and thyroid hormone receptor superfamily. Science, 1988; 240: 889-895
15. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev, 1999; 20: 649-688
16. Nakajima A, Wada A, Miki H et al: Endogenous PPAR-gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology, 2001; 120: 460-469
17. Thiemermann C, Wayman NS: Menarini Academy Cardiovascular Research Awards in Basic Science 2001: ligands of the orphan receptor peroxisome-proliferator activator-gamma reduce myocardial infarct size. Med Sci Monit, 2001; 7: 787-789
18. Wayman NS, Hattori Y, McDonald MC et al: Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J, 2002; 16: 1027-1040
19. Hayasbidani S, Tsutsui H, Shiomi T et al: Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation, 2002; 105: 868-873
20. Laufs U, Liao J: Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem, 1998; 273: 24266-24271
21. Wayman N, McDonald MC, Thompson AS et al: 5-aminoisoquinolinone, a potent inhibitor of poly (adenosine 5′-diphosphate ribose) polymerase, reduces myocardial infarct size. Eur J Pharmacol, 2001; 430: 93-100
22. Baller D, Bretschneider HJ, Hellige G: A critical look at currently used indirect indices of myocardial oxygen consumption. Basic Res Cardiol, 1981; 76: 163-181
23. Nachlas MM, Shnitka TK: Macroscopic identification of early myocardial infarcts by alterations in dehydrogenase activity. American journal pathology, 1963; 42: 379-405
24. Rossi A, Kapahi P, Natoli G et al: Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature, 2000; 403: 103-108
25. Zingarelli B, Hake PW, Denenberg A, Wong HR: Sesquiterpene lactone parthenolide, an inhibitor of IkappaB kinase complex and nuclear factor-kappaB, exerts beneficial effects in myocardial reperfusion injury. Shock, 2002; 17: 127-134
26. Izumi T, Saito Y, Kishimoto I et al: Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-kappaB activation and alleviates myocardial ischemia/reperfusion injury. J Clin Invest, 2001; 108: 203-213
27. Manning AM, Bell FP, Rosenbloom CL et al: NF-kappa B is activated during acute inflammation in vivo in association with elevated endothelial cell adhesion molecule gene expression and leukocyte recruitment. J Inflamm, 1995, 45: 283-296
28. Telek G, Ducroc R, Scoazec JY et al: Differential upregulation of cellular adhesion molecules at the sites of oxidative stress in experimental acute pancreatitis. J Surg Res, 2001; 96: 56-67
29. Sukhova GK, Williams JK, Libby L: Satins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterio Thromb Vasc Biol, 2002; 22
30. Laufs U, Gertz K, Dirnagl U et al: Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res, 2002; 942: 23-30
31. Laufs U, Gertz K, Nickenig G et al: Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decrease platelet activation, and protects from cerebral ischemia in normcholesterolemic mice, Stroke, 2000; 31: 2442-2449
32. Napoli Di, Antonio Di, Taccardi A et al: Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res, 2001; 51: 283-293
33. Bell RM, Yellon DM: Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Col Cardiol, 2003; 41: 508-515